GPT and metabolic syndrome: All the 85 patients (including patients in patient group and two drug groups before intervention) were overweight or had obesity with significantly increased BW, BMI, WC, and HC, and were diagnosed as having dyslipidemia with significantly increased TG, TC and LDL-C (only found in orlistat and ezetimibe group) and significantly decreased HDL-C, as well as liver dysfunction presenting as increased γ-GT and ALT, and the ALB in orlistat and ezetimibe groups were significantly lower than controls.